Gilead Sciences (NASDAQ:GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Gilead Sciences has announced new data from its pivotal Phase III PURPOSE 2 trial providing further details on the efficacy, ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

He said Gilead plans to file before the end of this year for U.S. regulatory approval of lenacapavir, a twice-yearly ...

Together, they accounted for more than 50% of Gilead's consolidated product sales. In addition, lenacapavir, Gilead's twice-yearly HIV prevention product, for which promising results were ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.